Membership

December 2008

Dear Colleagues:
The 1st ASTRO/IASLC/University of Chicago, ASCO Multidisciplinary Symposium in Thoracic Oncology was recently held in Chicago, November 13-15, 2008. The conference, chaired by Drs. Everett Vokes and Stephen Hahn, was a great success. About 800 scientists participated at the meeting and much new data was presented. The virtual meeting will be available at IASLC’s website in January 2009. The Board of Directors would like everyone to pay attention to the upcoming dead-line for the IASLC Fellowship applications (see below) on January 10, 2009. We will encourage Fellows and Young Investigators to apply. IASLC has recently launched a new website. Please visit our new website; comments can be sent to pia.hirsch@uchsc.edu. The IASLC Board of Directors reminds all members that the deadline for sending abstracts to the 13th WCLC in San Francisco 2009 is March 13, 2009. We hope to see many abstracts submitted to this conference. For the 16th WCLC 2015 six proposals were received. The decision for the hosting site will be made in June 2009. Based on the success of the IASLC/ESMO joint meeting earlier this year, a joint meeting is planned in Geneva, Switzerland, April 28-May 1, 2010. Finally, the IASLC Board of Directors wishes all the members Happy Holidays and a healthy and prosperous year 2009!
Fred R. Hirsch, MD, PhD
Editor, IASLC Newsletter

IASLC Fellowship/Young Investigator Awards:
The IASLC Fellowship/Young Investigator application was announced on the website www.iaslc.org October 1st, 2008.
Deadline for application is January 10th, 2009. The announcement and application will be posted in English, Chinese and Japanese.
2008 Chicago Multidisciplinary Symposium in Thoracic Oncology - November 13-15, 2008
There will be a link on our website, www.iaslc.org, in January. 2009.

Names
George Simon

 

George R. Simon, MD, FACP, FCCP is joining Fox Chase’s Medical Oncology Department as Director of Thoracic Oncology, October 2008. New contact information: george.simon@fccc.edu

 

 

 

 

 

 

 

Norman Bleehen

 

Obituary: Professor Norman Bleehen 1930 - 2008
It was with great sadness IASLC recently received the message that our long time member, Dr. Norman Bleehen died February 1st, 2008. Dr. Bleehen was a member of the IASLC Board of Directors from 1978 – 1994 and Vice-President of the organization. Norman Bleehen was a clinical and research oncologist and a founder of academic oncology in the United Kingdom, whose reputation was acknowledged both nationally and internationally. He was the first Cancer Research Campaign Professor of Clinical Oncology and Radiotherapeutics in the University of Cambridge, where his department was particularly involved with studies on the treatment of lung and brain cancer. As chairman of the MRC Cancer Therapy Committee he realized the importance of rigorous evaluation of new drugs and treatments, particularly in lung cancer. Dr. Bleehen was chairman of the British Association for Cancer Research, president of the International Society for Radiation Oncology, and consultant to the Research Co-ordination Group of the International Atomic Energy Agency for the Improvement of Cancer Therapy. He represented the UK government in the Europe Against Cancer Programme and was particularly passionate about smoking prevention campaigns. It is therefore particularly sad that, despite being a lifelong non-smoker, he developed terminal lung cancer. He was on the editorial board of a number of major journals. He published six books and over 400 papers, chapters and editorials. He is survived by his wife.

 

Journal of Thoracic Oncology (JTO); December 2008:
Editorial
1371
Case-Control Study Design: What, when, and why?
Jayawant N. Mandrekar, PhD; Sumithra J. Mandrekar, PhD

1373
Should We Recommend Surgery to Patients with Limited Small
Cell Carcinoma of the Esophagus?
Aminah Jatoi, MD; Robert C. Miller, MD

1377
Controversies in Bronchogenic Carcinoma Following Lung
Transplantation: Type of Transplant Operation and Role of
Screening.
Selim M. Arcasoy, MD, FACP, FCCP

Pathway of the Month
1379
The CXCR4/SDF-1 Chemokine Receptor Axis: A New Target
Therapeutic for Non-small Cell Lung Cancer.
Shannon Otsuka, BSc; Gwyn Bebb, BMBCh, PhD, FRCPC

IASLC Staging Committee Article
1384
Visceral Pleural Invasion: Pathologic Criteria and Use of Elastic
Stains: Proposal for the 7th Edition of the TNM Classification for
Lung Cancer.
William D. Travis, MD; Elisabeth Brambilla, MD; Ramon Rami-Porta, MD; Eric Vallières,
MD; Masahiro Tsuboi, MD; Valerie Rusch, MD; Peter Goldstraw, FRCS; on behalf of the
International Staging Committee

Original Article
1391
Epidemiology of Non-small Cell Lung Cancer in Asian
Americans: Incidence Patterns Among Six Subgroups by
Nativity.
Dan J. Raz, MD, MAS; Scarlett L. Gomez, PhD; Ellen T. Chang, ScD; Jae Y. Kim, MD;
Theresa H. M. Keegan, PhD; Jane Pham, MPH; Jasleen Kukreja, MD, MPH; Robert A.
Hiatt, MD; David M. Jablons, MD

1398
Cannabis Smoking and Risk of Lung Cancer in Men: A Pooled
Analysis of Three Studies in Maghreb.
Julien Berthiller, MSc; Kurt Straif, MD, PhD; Mathieu Boniol, PhD; Nicolas Voirin, MSc;
Veronique Benhaïm-Luzon, AA; Wided Ben Ayoub, MD; Iman Dari, MD; Slimane
Laouamri, MD; Mokhtar Hamdi-Cherif, MD, PhD; Mohamed Bartal, MD, PhD; Fahrat Ben
Ayed, MD, PhD; Annie J. Sasco, MD, PhD

1404
Bronchogenic Carcinoma after Lung Transplantation:
Characteristics and Outcomes.
Omar A. Minai, MD; Sonia Shah, MD; Peter Mazzone, MD; Marie M. Budev, MD;
Debasis Sahoo, MBBS; Sudish Murthy, MD; David Mason, MD; Gosta Pettersson, MD;
Atul C. Mehta, MBBS

1410
Reclassification of Neuroendocrine Tumors Improves the
Separation of Carcinoids and the Prediction of Survival.
Birgit Guldhammer Skov, MD, DrMSci; Mark Krasnik, MD; Sylvie Lantuejoul, MD, PhD;
Torsten Skov, MD, PhD; Elisabeth Brambilla, MD, PhD

1416
Combined Evaluation of Postoperative Serum Levels of
Carcinoembryonic Antigen Less than or Equal to 2.5 ng/ml and
Absence of Vascular Invasion may Predict no Recurrence of
Stage I Adenocarcinoma Lung Cancer.
Kosuke Kashiwabara, MD; Syoh Saeki, MD; Ji-ichiro Sasaki, MD; Masanobu Nomura,
MD; Hirotsugu Kohrogi, MD

1421
Validity of International Association for the Study of Lung
Cancer Proposals for the Revision of N Descriptors in Lung
Cancer.
Jin Gu Lee, MD; Chang Young Lee, MD; Mi Kyung Bae, MD; In Kyu Park, MD; Dae Joon
Kim, MD; Kil Dong Kim, MD; Kyung Young Chung, MD

1427
11C-Acetate can be Used in Place of 18F-Fluorodeoxyglucose
for Positron Emission Tomography Imaging of Non-small Cell
Lung Cancer with Higher Sensitivity for Well-Differentiated
Adenocarcinoma.
Hiroaki Nomori, MD, PhD; Hidekatsu Shibata, MD; Kimiichi Uno, MD, PhD; Kenichi
Iyama, MD, PhD; Yumi Honda, MD, PhD; Rumi Nakashima, MD, PhD; Kazuya
Sakaguchi, PhD; Tomoyuki Goya, MD, PhD; Iwao Takanami, MD, PhD; Kiyoshi Koizumi,
MD, PhD; Takashi Suzuki, MD, PhD; Masahiro Kaji, MD, PhD; Hirotoshi Horio, MD, PhD

1433
Use of Maximum Intensity Projections (MIPs) for Target
Outlining in 4DCT Radiotherapy Planning.
Rebecca Muirhead, MBChB, MRCP; Stuart G. McNee, PhD; Carrie Featherstone,
MBChB, MRCP, FRCR; Karen Moore, BSc; Sarah Muscat, PhD

1439
Efficacy and Safety of Erlotinib Monotherapy for Japanese
Patients with Advanced Non-small Cell Lung Cancer: A Phase II
Study.
Kaoru Kubota, MD, PhD; Yutaka Nishiwaki, MD; Tomohide Tamura, MD; Kazuhiko
Nakagawa, MD; Kaoru Matsui, MD; Koshiro Watanabe, MD, PhD; Toyoaki Hida, MD;
Masaaki Kawahara, MD; Nobuyuki Katakami, MD; Koji Takeda, MD; Akira Yokoyama,
MD; Kazumasa Noda, MD; Masahiro Fukuoka, MD; Nagahiro Saijo, MD, PhD

1446
Epidermal Growth Factor Receptor-Related Tumor Markers and
Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer:
An Analysis of Patients from German Centers in the TRUST
Study.
Claus-Peter Schneider, MD; David Heigener, MD; Kathrin Schott-von-Römer, MD; Sylvia
Gütz, MD; Eckart Laack, MD; Werner Digel, MD; Wolf-Rüdiger Guschall, MD; Andreas
Franke, MD; Heinrich Bodenstein, MD; Claudia Schmidtgen, PhD; Martin Reck, MD, PhD

1454
Phase II Study of Celecoxib and Docetaxel in Non-small Cell
Lung Cancer (NSCLC) Patients with Progression after Platinum-
Based Therapy.
Bryan J. Schneider, MD; Gregory P. Kalemkerian, MD; Michael J. Kraut, MD; Antoinette
J. Wozniak, MD; Francis P. Worden, MD; Daryn W. Smith, MS; Wei Chen, PhD; Shirish
M. Gadgeel, MD

1460
Primary Small Cell Carcinoma of the Esophagus.
Jima Lv, MD; Jun Liang, MD; Jinwan Wang, MD; Luhua Wang, MD; Jie He, MD; Zefen
Xiao, MD; Weibo Yin, MD

Image of the Month
1466
Hemoptysis in a Patient with Melanoma and Pulmonary
Infiltrates.
J Francis Turner Jr, MD, FACP, FCCP, FCCM; Wolfram Samlowski, MD; Laura L.
Bilodeau, MD

State of the Art
Concise Review
1468
The Prognostic and Predictive Role of Histology in Advanced
Non-small Cell Lung Cancer: A Literature Review.
Fred R. Hirsch, MD, PhD; Anna Spreafico, MD; Silvia Novello, MD, PhD; Mary Dugan
Wood, PhD; Lorinda Simms, MSc, PStat; Mauro Papotti, MD

Case Report
1482
Pulmonary Tumor Embolism: A Rare Cause of Acute Right Heart
Failure with Elevated d-Dimers.
Robert Kridel, MD; Samir Myit, MD; Jean-Claude Pache, MD; Jean-Michel Gaspoz, MD,
MSc

1484
Paraneoplastic Limbic Encephalitis due to Thymic Carcinoid.
Melissa Davis, BA; James G. Ravenel, MD

IASLC Election 2009:
Please note that in 2009, new members of the Board of Directors will be elected for the period of 2009-2011. Among the new members of the Board of Directors is the President Elect from Europe. In 2009 there will be an election for a President-Elect from Europe and 8 new Board members. The Board of Directors has a total of 15 Directors, 5 each from North America, Europe and Asia/Rest of World. The members should be diverse in terms of specialty and gender. The following Board of Directors will remain as members of the Board from 2009-2011. The election will take place in the Spring, 2009.
North America
Joan Schiller, medical oncology
Harvey Pass, surgery
Europe
Elisabeth Brambilla, pathology
Wilfried Eberhardt, medical oncology
Asia/ROW
Tony Mok, medical oncology
Kwun Fong, medical oncology
Masahiro Tsuboi, surgery
Thus, the IASLC membership will need to elect 3 Board members from North
America, 3 from Europe and 2 from Asia/Rest of the World.

Upcoming Workshops:
2009
January 28-30, 2009 7th Annual British Thoracic Oncology Group Meeting Location: Clontarf Castle - Dublin, Ireland Contact: Dawn McKinley Email: dawn.mckinley@uhl-tr.nhs.uk Phone: 0116 250 2811 Fax: 0116 250 2810

February 18-21, 2009 9th Annual Targeted Therapies of the Treatment of Lung Cancer meeting Location: The Fairmont Miramar Hotel - Santa Monica, California For more information: pia.hirsch@ucdenver.edu

April 1-5, 2009 4th IASLC International Meeting on Targeted Therapies in Lung Cancer Location: Saint Paul de Vence, France For more information: pia.hirsch@ucdenver.edu

August 28-29, 2009 Simposio Internacional Pos Mundial Cancer de Pulmao Location: Salvador, Bahia, Brazil Contact: Victor Email: victor@marcativa.com

New IASLC member October – November 2008:
Argentina
India
Spain
United States
Eduardo Arnoldo Richardet
Rohit Joshi
Nuria Vinolas
James Urbanic
Domingo Javier Chimondeguy
Japan
Cinta Pallares Curto
Meredith Tennis
Australia
Takashi Iwata
Ernest Nadal Alforja
Elizabeth Blanchard
Henry Marshall
Yoshitaka Fujii
Victoria Folgueras
Todd Demmy
China
Ogino Atsuko
Guillermo Alonso
Andrea Ferris
Benny (Chung-ying) Zee
Hirokazu Watanabe
Javier Puente Vazquez
Fabien Gaire
France
Netherlands
Monica Guillot Morales
Victoria Villaflor
Maciej Rotarski
Nico Van Walree
Mariano Provencio
Takaaki Sasaki
Cecile Dujon
Remge Pieterman
Switzerland
Robert Cameron
Germany
Philippines
Patrizia Froesch
Pierre R. Theodore
Diya Hasan
Felycette Gay Lapus
Paul-Martin Putora
David Shelton
Greece
South Korea
Pauline Gerard-Duhard
Janine Cataldo
Emmanouilides Christos
Sang Hoon Han
United Kingdom
Raffaele Califano
Adrian Draper